Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance

Hepatology International

Volumn 5, Issue 2, 2011, Pages 654-663

  Perrillo, Robert P ^a   Hann, Hie Won ^b   Schiff, Eugene ^c   Mutimer, David ^d   Willems, Bernard ^e   Leung, Nancy ^f   Lee, William M ^g   Dixon, Susan ^h   Woessner, Mary ⁱ   Brosgart, Carol L ^j   Condreay, Lynn D ⁱ   Gardner, Stephen D ⁱ  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e Hôpital Saint Luc   (Canada)

^f ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h GLAXOSMITHKLINE   (United Kingdom)

ⁱ GLAXOSMITHKLINE   (United States)

^j GILEAD SCIENCES   (United States)

more..

Author keywords

Adefovir dipivoxil; Chronic hepatitis B; Combination therapy; Lamivudine; Resistance

Indexed keywords

ADEFOVIR DIPIVOXIL; ISOLEUCINE; LAMIVUDINE; METHIONINE; PLACEBO; VALINE; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS MUTATION;

EID: 79956287125     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-010-9228-9     Document Type: Article

References (25)

1. D Lavanchy 2004 Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures J Viral Hepatol 11 97 107 10.1046/j.1365-2893.2003.00487.x 1:STN:280: DC%2BD2c7gs1Whug%3D%3D (Pubitemid 38365759)
2. J Dienstag ER Schiff TL Wright RP Perrillo HWL Hann Z Goodman L Crowther LD Condreay M Woessner M Rubin NA Brown 1999 Lamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1256 1263 10528035 10.1056/NEJM199910213411702 1:CAS:528:DyaK1MXnt1Cqs78%3D (Pubitemid 29489740)
3. CL Lai RN Chien NW Leung TT Chang R Guan DI Tai KY Ng PC Wu JC Dent J Barber SL Stephenson F Gray 1998 A one-year trial of lamivudine for chronic hepatitis B New Engl J Med 339 61 68 9654535 10.1056/NEJM199807093390201 1:CAS:528:DyaK1cXkvVSqtbY%3D (Pubitemid 28304879)
4. SW Schalm J Heathcote J Cianciara G Farrell M Sherman B Willems A Dhillon A Moorat J Barber DF Gray 2000 Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomized trial Gut 46 562 568 10716688 10.1136/gut.46.4.562 1:CAS:528:DC%2BD3cXis1ems7Y%3D (Pubitemid 30305823)
5. M Jonas D Kelley J Mizerski IB Badia JA Areias KB Schwarz NR Little MJ Greensmith SD Gardner MS Bell EM Sokal 2002 Clinical trial of lamivudine in children with chronic hepatitis B N Engl J Med 346 1706 1713 12037150 10.1056/NEJMoa012452 1:CAS:528:DC%2BD38XktVansLc%3D (Pubitemid 34547484)
6. Liaw Y-F, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, D Gray F, Sabbat, J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531, 1587
7. R Perrillo E Schiff E Yoshida A Statler K Hirsch T Wright K Gutfreund P Lamy A Murray 2000 Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants Hepatology 32 129 134 10869300 10.1053/jhep.2000.8626 1:CAS:528:DC%2BD3cXltFWgs7c%3D (Pubitemid 30432377)
8. MG Peters HW Hann P Martin J Heathcote P Buggisch R Rubin M Bourliere K Kowdley C Trepo DF Gray M Sullivan K Kleber R Ebrahimi S Xiong CL Brosgart 2004 Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 91 101 14699491 10.1053/j.gastro.2003.10.051 1:CAS:528:DC%2BD2cXhtFGntLo%3D (Pubitemid 38040727)
9. R Perrillo HW Hann D Mutimer B Willems N Leung WM Lee A Moorat S Gardner M Woessner E Bourne CL Brosgart E Schiff 2004 Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus Gastroenterology 126 81 90 14699490 10.1053/j.gastro.2003.10.050 1:CAS:528:DC%2BD2cXhtFGntL0%3D (Pubitemid 38040726)
10. P Lampertico M Viganò E Manenti M Iavarone G Lunghi M Colombo 2005 Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine Hepatology 42 1414 1419 16317671 10.1002/hep.20939 1:CAS:528:DC%2BD2MXhtlGns7vP (Pubitemid 43260045)
11. SK Ono-Nita N Kato Y Shiratori T Masaki KH Lan FJ Carrilho M Omata 1999 YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: a study by in vitro full-length viral DNA transfection Hepatology 29 939 945 10051501 10.1002/hep.510290340 1:CAS:528: DyaK1MXhvFyjsLY%3D (Pubitemid 29109613)
12. C Pallier L Castera A Soulier C Hézode P Nordmann D Dhumeaux JM Pawlotsky 2006 Dynamics of hepatitis B virus resistance to lamivudine J Virol 80 643 653 16378967 10.1128/JVI.80.2.643-653.2006 1:CAS:528:DC%2BD28XivVOluw%3D%3D (Pubitemid 43062877)
13. D Mutimer D Pillay P Shields P Cane D Ratcliffe B Martin S Buchan L Boxall K O'Donnell J Shaw S Hubscher E Elias 2000 Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient Gut 46 107 113 10601065 10.1136/gut.46.1.107 1:STN:280:DC%2BD3c%2FmvFGisg%3D%3D (Pubitemid 30307687)
14. Y Benhamou M Bochet V Thibault M Calvez H Fievet P Vig CS Gibbs C Brosgart J Fry H Namini C Katlama T Poynard 2001 Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open label pilot study Lancet 358 718 723 11551579 10.1016/S0140-6736(01)05840-8 1:CAS:528:DC%2BD3MXms1Omtr4%3D (Pubitemid 32823401)
15. ER Schiff CL Lai S Hadziyannis P Neuhaus N Terrault M Colombo HL Tillmann D Samuel S Zeuzem L Lilly M Rendina JP Villeneuve N Lama C James MS Wulfsohn H Namini C Westland S Xiong GS Choy S Van Doren J Fry CL Brosgart 2003 Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients Hepatology 38 1419 1427 14647053 1:CAS:528: DC%2BD2cXpsVGk (Pubitemid 37466968)
16. MI Allen J Gauthier M DesLauriers EJ Bourne KM Carrick F Baldanti LL Ross MW Lutz LD Condreay 1999 Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine J Clin Microbiol 37 3338 3347 10488202 1:CAS:528:DyaK1MXmsFektLo%3D (Pubitemid 29455230)
17. T Shaw A Bartholomeusz S Locarnini 2006 HBV drug resistance: mechanism, detection and interpretation J Hepatol 44 593 606 16455151 10.1016/j.jhep.2006. 01.001 1:CAS:528:DC%2BD28XhsFKktrc%3D (Pubitemid 43227885)
18. ASF Lok CL Lai N Leung GB Yao ZY Cui ER Schiff JL Dienstag EJ Heathcote NR Little DA Griffiths SD Gardner M Castiglia 2003 Long-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714 1722 14724824 10.1053/j.gastro.2003.09.033 1:CAS:528:DC%2BD2cXhtVOrug%3D%3D (Pubitemid 37500436)
19. Z Fabien R Perrillo 2008 Hepatitis B: reflections on the current approach to antiviral therapy J Hepatol 48 S2 S19 10.1016/j.jhep.2008.01.011
20. A Snow V Thibault X Qi Y Zhu CE Westland S Arterbrun 2005 Combination of adefovir dipivoxil (ADV) and lamivudine (LAM) prevented emergence of ADV resistance mutations in chronic hepatitis B (CHB) patients with LAM-Resistant HBV Gastroenterology 128 M945
21. SK Fung HB Chae RJ Fontana H Conjeevaram J Marrero K Oberhelman M Hussain AS Lok 2006 Virologic response and resistance to adefovir in patients with chronic hepatitis B J Hepatol 44 283 290 16338024 10.1016/j.jhep.2005.10.018 1:CAS:528:DC%2BD28Xktl2qsA%3D%3D (Pubitemid 43069209)
22. ASF Lok BJ McMahon 2007 AASLD practice guidelines, chronic hepatitis B Hepatology 47 507 539 10.1002/hep.21513 (Pubitemid 46374607)
23. JJY Sung JY Lai S Zeuzem WC Chow EJ Heathcote RP Perrillo CL Brosgart MA Woessner SA Scott DF Gray SD Gardner 2008 Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B J Hepatology 48 728 735 10.1016/j.jhep.2007.12.026 1:CAS:528:DC%2BD1cXktVGrtbg%3D
24. S Xiong C Flores H Yang JJ Toole CS Gibbs 1998 Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro Hepatology 28 1669 1673 9828233 10.1002/hep.510280629 1:CAS:528:DyaK1cXotFSgt7Y%3D (Pubitemid 28549139)
25. DJ Tenney SM Levine RE Rose AW Walsh SP Weinheimer L Discotto M Plym K Pokornowski CF Yu P Angus A Ayres A Bartholomeusz W Sievert G Thompson N Warner S Locarnini RJ Colonno 2004 Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine Antimicrob Agents Chemother 48 3498 3507 15328117 10.1128/AAC.48.9.3498-3507.2004 1:CAS:528:DC%2BD2cXnsVehsL0%3D (Pubitemid 39129351)